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THREE DIMENSIONAL ECHOCARDIOGRAPHY A NOVEL 
TECHNIQUE FOR RHEUMATIC MITRAL VALVE STENOSIS 
EVALUATION 
INTRODUCTION  
Mitral stenosis is characterized by restriction of blood flow from the left 
atrium (LA) to the left ventricle (LV) as a result of a narrowed mitral passage. It is an 
acquired valvular defect; it is usually a consequence of rheumatic heart disease, 
though cases of congenital mitral stenosis are occasionally encountered. The 
fundamental treatment for rheumatic mitral stenosis2 is to increase the mitral valve 
area (MVA) by means of percutaneous transvenous mitral commissurotomy or by 
surgical valve replacement. In order to establish the time of surgery and an optimal 
management, it is essential to make an appropriate and accurate assessment of its 
severity.  
At present, the invasive measurement of the mitral valve area is based on the 
Gorlin formula. This method has been used as the invasive reference method to assess 
the severity of the rheumatic mitral stenosis. However, it is an invasive method that 
may result in complications and inaccuracies. Recently, 3DFull volume Planimetry 
has become an available technique in many echocardiography labs, providing 
numerous advantages in the assessment of valvular disease. 
Zamorano J14, Cordeiro  P, et al studied in 2004,in Eighty patients with 
Rheumatic Mitral stenosis comprised (76 women; 50.6 +/- 13.9 years). When 
compared with all other echo-Doppler methods1, RT3D had the best agreement with 
the invasively determined MVA (average difference between both methods and limits 
of agreement: 0.08 cm(2) [-0.48 to 0.6]) 
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In another study, Binder16et al. used a first generation real-time 3D 
echocardiography machine (Volumetrics )in which 3D planimetry proved to be a fast, 
easy, accurate, and reproducible technique in comparison to 2D planimetry and 
pressure half-time-derived MVA.  
 
  Recent Studies showed that in last few years, three-dimensional 
echocardiography 2 has become an accurate tool for mitral stenosis assessment. 
Accuracy of 3DEcho planimetry is superior to the accuracy of the invasive Gorlin's 
method for mitral valve area (MVA) measurements16 when a median value obtained 
from two-dimensional planimetry, pressure half-time1, and proximal isovelocity 
surface area method, hence used as the gold standard. 3DEcho improves MVA 
measurement particularly in less experienced operators compared with experienced 
operators. 3D Echo also improves the measurement of MVA in patients with calcific 
mitral stenosis by means of colour planimetry of the flow stream. Comparison of 
mitral valve volumes measured by 3DEcho in patients with critical and without 
critical stenosis has shown significantly larger volumes in patients with critical 
stenosis. 
In a recent study, Zamorano et al14,15. have studied 29 patients with rheumatic 
mitral stenosis in a multi-centre study before and after PTMC with second generation 
trans thoracic real-time 3D echocardiography, found that real-time 3D 
echocardiography was the most accurate ultrasound technique for measuring MVA, 
with a better pre- and post-procedural agreement with the invasively (Gorlin) derived 
MVA, compared to 2D planimetry and pressure half-time-derived MVA1. The success 
rate for real-time 3D echocardiography15 in 29 consecutive mitral stenosis patients in 
two centres was 100% for all methods, making real-time 3D echocardiography a 
feasible technique, with an acceptable acquisition and analysis time of approximately 
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20 min. Post-PTMC the agreement with the Gorlin-derived MVA was much better, in 
contrast to 2D planimetry and pressure half-time-derived MVA1, which may be due to 
the hemodynamic and compliance changes affecting the latter, as was observed 
before. 
 
In our part of the world there were limited number of studies even though 
there is much necessity to know more in detail about the Rheumatic Mitral valve 
disease15 which is more prevalent. 
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REVIEW OF LITERATURE 
ANATOMY OF THE MITRAL VALVE 
It is important to recognize that the leaflets of the mitral valve constitute only 
a portion of the mitral valve apparatus and that diseases resulting in mitral 
dysfunction often are caused by abnormalities in the overall apparatus rather than in 
the actual leaflets. The components of the mitral apparatus include the mitral annulus, 
the leaflets, chordate tendineae , papillary muscles, and the underlying ventricular 
wall. Pathologic changes in any of these components of the mitral valve apparatus can 
result in mitral valve dysfunction. The classic form of mitral valve disease is 
rheumatic heart disease, which involves predominantly the leaflets and chordae.  
 
There are two mitral valve leaflets, typically referred to as anterior and 
posterior. The mitral leaflet should be viewed not as a two-leaflet structure but as a 
six-scallop structure. Clinically, the most easily understood and clinically useful 
description of mitral valve anatomy involves dividing it into six scallops, three each 
for the anterior and posterior leaflet, designated as scallop 1, 2, and 3. Scallop 1 is 
most lateral and scallop 3 is most medial. Chordae attach throughout the entire length 
of the coaptation line of each of the mitral valve leaflets and insert into the tips of the 
papillary muscles. 
 
Anatomically, there are two major papillary muscles, each of which may have 
several heads. The antero lateral papillary muscle provides chordae to the antero 
lateral half of both mitral leaflets. The postero medial papillary muscle provides 
chordae to the postero medial aspect of both leaflets. There is substantial variability 
from patient to patient in the exact number of chordae and the percentage of chords 
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that are devoted to the anterior and posterior leaflets, but in general both papillary 
muscles provide chordal  attachments to a portion of each of the leaflets.  
 Approximately 60% of patients with pure mitral stenosis have a history of  rheumatic 
fever2, although in some parts of the developing world, the initial episode of 
rheumatic fever may be unrecognized due to scarcity of health-care resources. The 
diagnosis of rheumatic fever is made using the Jones criteria in a patient with a 
history of streptococcal infection. To make the diagnosis, two major criteria or one 
major and two minor criteria must be met. 
 
Figure.1 Macroscopic appearance of Rheumatic Mitral Valve2 
 
In addition to the major and minor criteria listed above, there must be evidence 
of streptococcal infection 2–4 weeks earlier (either a positive throat culture for group 
A beta-hemolytic streptococci, a positive rapid streptococcal antigen test, or elevated 
streptococcal antibody titers).  In developing areas of the Indian subcontinent, Middle 
East, and Asia, rheumatic fever remains more frequent.  
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Etiology of Mitral Stenosis2 
Acquired 
• Rheumatic heart disease (vast majority of cases) 
• Calcific mitral stenosis 
• Hypereosinophilia 
• Cafergot toxicity 
• SLE, malignant sarcoid, mucopolysaccharidosis 
• Active infective endocarditis, Whipple’s disease 
 
Congenital 
• Parachute mitral valve complex 
• Shone’s complex: parachute mitral valve with supra-valvar mitral ring, sub-
valvular aortic stenosis and coarctation of the aorta  
In Rheumatic Mitral Stenosis, at autopsy with characteristic findings  like 
thickened mitral valve, thickened  chordae  tendineae, hypertrophied left ventricular 
myocardium are seen. Almost all cases of mitral stenosis are due to disease in the 
heart secondary to rheumatic fever and the consequent rheumatic heart disease. 
Uncommon causes of mitral stenosis are calcification of the mitral valve leaflets, and 
as a form of congenital heart disease. However, there are primary causes of mitral 
stenosis that emanate from a cleft mitral valve. Other causes include Bacterial endo  
carditis where the vegetations may favor increased risk of stenosis. It is the most 
common valvular heart disease in pregnancy.  
 
Patho physiology  
The normal area of the mitral valve orifice is about 4 to 6 cm2. In normal 
cardiac physiology, the mitral valve opens during left ventricular diastole, to allow 
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blood to flow from the left atrium to the left ventricle. A normal mitral valve will not 
impede the flow of blood from the left atrium to the left ventricle during (ventricular) 
diastole, and the pressures in the left atrium and the left ventricle during ventricular 
diastole will be equal. The result is that the left ventricle gets filled with blood during 
early ventricular diastole, with only a small portion of extra blood contributed by 
contraction of the left atrium (the "atrial kick") during late ventricular diastole. When 
the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of 
blood into the left ventricle, creating a pressure gradient across the mitral valve. This 
gradient may be increased by increases in the heart rate or cardiac output. As the 
gradient across the mitral valve increases, the amount of time necessary to fill the left 
ventricle with blood increases. Eventually, the left ventricle requires the atrial kick to 
fill with blood. As the heart rate increases, the amount of time that the ventricle is in 
diastole and can fill up with blood (called the diastolic filling period) decreases. When 
the heart rate goes above a certain point, the diastolic filling period is insufficient to 
fill the ventricle with blood and pressure builds up in the left atrium, leading to 
pulmonary congestion. 
 
When the mitral valve area goes less than 1 cm2, there will be an increase in 
the left atrial pressures (required to push blood through the stenotic valve). Since the 
normal left ventricular diastolic pressures is about 5 mmHg, a pressure gradient across 
the mitral valve of 20 mmHg due to severe mitral stenosis will cause a left atrial 
pressure of about 25 mmHg. This left atrial pressure is transmitted to the pulmonary 
vasculature and causes pulmonary hypertension. Pulmonary capillary pressures in this 
level cause an imbalance between the hydrostatic pressure and the oncotic pressure, 
leading to extravasations of fluid from the vascular tree and pooling of fluid in the 
lungs (congestive heart failure causing pulmonary oedema). The constant pressure 
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overload of the left atrium will cause the left atrium to increase in size. As the left 
atrium increases in size, it becomes more prone to develop atrial fibrillation. When 
atrial fibrillation develops, the atrial kick is lost (since it is due to the normal atrial 
contraction). In individuals with severe mitral stenosis, the left ventricular filling is 
dependent on the atrial kick. The loss of the atrial kick due to atrial fibrillation can 
cause a precipitous decrease in cardiac output and sudden congestive heart failure. 
Patients with mitral stenosis prompts a series of hemodynamic changes that frequently 
cause deterioration of the patient's clinical status. A reduction in cardiac output, 
associated with acceleration of heart rate and shortening of the diastolic time, 
frequently leads to congestive heart failure. In addition, when AF sets in, systemic 
embolization becomes a real danger. Mitral stenosis typically progresses slowly (over 
decades) from the initial signs of mitral stenosis to NYHA functional class II 
symptoms to the development of atrial fibrillation to the development of NYHA 
functional class III or IV symptoms. Once an individual develops NYHA class III or 
IV symptoms, the progression of the disease accelerates and the patient's condition 
deteriorates. 
 
Natural History of Mitral Stenosis 
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Secondary Features of Mitral Stenosis  
Chronic mitral stenosis results in several common and easily recognized 
secondary features, the overwhelming majority of which are related to an increase in 
left atrial pressure. Chronic elevation in left atrial pressure results in left atrial dilation 
and eventual fibrosis of the atrial myocardium. Over time, fibrosis of the atrial 
myocardium results in decreased atrial contraction and serves as a substrate for 
development of atrial fibrillation. Dilation of the left atrium occurs both in the atrial 
body and left atrial appendage. The combination of atrial and atrial appendage 
dilation with decreasing mechanical function results in stasis of the blood with an 
enhanced propensity to thrombus formation, most commonly in the left atrial 
appendage. This typically appears as a swirling mass of echoes in the body of the left 
atrium, referred to as spontaneous echo contrast, and is often maximal in the left atrial 
appendage. 
Current opinion suggests that spontaneous echo contrast and stasis of the 
blood are precursors to thrombus formation in the left atrium that carry a nearly 
equivalent risk of thrombo embolic disease, especially if seen in the presence of atrial 
fibrillation. When evaluating a patient for a possible left atrial appendage thrombus, it 
is important to recognize the range in anatomic variability of the atrial appendage. 
Traditionally, the left atrial appendage has been considered a single-lobe structure 
with varying degrees of trabeculation due to pectinate muscles. It is now well 
recognized that the left atrial appendage has multiple lobes in a substantial percentage 
(>30%) of patients. This raises several concerns when evaluating patients for a left 
atrial appendage thrombus. The first is that all lobes of the appendage must be 
identified and examined. The second issue is the need to recognize the septation tissue 
between appendage lobes as normal tissue and not as protruding thrombus.  
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Atrial Fibrillation 
A frequent sequel of left atrial dilation is atrial fibrillation, which can be either 
intermittent or persistent. In the presence of atrial fibrillation, there is a loss of 
organized mechanical activity of the left atrium. This intensifies the tendency to form 
spontaneous echo contrast and thrombus.  The fibrillatory mechanical activity of the 
atrium can be appreciated by either two-dimensional visualization or M-mode 
echocardiography of the left atrial wall.  Additionally, Doppler echocardiography at 
the mouth of the atrial appendage reveals indirect evidence of the reduction in 
mechanical force due to atrial fibrillation. Marked reduction in velocity and volume of 
flow out of the left atrial appendage compared with velocities seen in normal sinus 
rhythm and is the anatomic/physiologic basis for stasis and formation of clot. Patients 
with atrial fibrillation and relatively intact atrial appendage transport function as 
documented by preserved emptying velocities (>50 cm/sec) are less likely to have 
spontaneous contrast (and presumably thrombosis) than are those with reduced atrial 
appendage velocities.  
 
Secondary Pulmonary Hypertension 
An additional sequel of long-standing severe mitral stenosis is secondary 
pulmonary hypertension. In the early phases, this is due in large part to reactive 
changes in pulmonary vascular resistance and is reversible with correction of mitral 
stenosis. In long-standing severe mitral stenosis, a fixed component occurs, and in this 
instance, pulmonary artery systolic hypertension may be only partially reversible. 
Echo cardio graphic manifestations of secondary pulmonary hypertension in mitral 
stenosis are similar to those seen in pulmonary hypertension of any cause. Concurrent 
tricuspid regurgitation is present in the majority of these patients, usually due to right 
ventricular dilation and less often due to direct involvement of the tricuspid valve by 
the rheumatic process. 
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Two-Dimensional Echocardiography in Rheumatic Mitral Stenosis10,21 
The classic findings of rheumatic mitral stenosis involve thickening and fusion 
of the mitral valve commissural edges and chordae. This results in characteristic 
abnormalities of the mitral leaflet opening motion. Normally, the anterior and 
posterior leaflets open with a motion pattern that involves maximal excursion at the 
leaflet tips. In mitral stenosis, due to commissural fusion, the leaflets open with a 
doming motion. In rheumatic heart disease, the open anterior leaflet has also been 
described as having a hockey stick  appearance. Initially, this results in reduction of 
the orifice and conversion of the mitral leaflet chordal apparatus from a tubular 
channel to a funnel-shaped orifice. It should be recognized that the limiting factor in 
flow from the left atrium to the left ventricle will be the orifice of the mitral valve and 
chordae at their junction. The degree of chordal thickening and mitral valve 
commissural fusion is highly variable. Over time, there is progressive fibrosis at the 
initial site of fusion as well as throughout the more distal chordae and more proximal 
leaflets. Eventually, this results in stiffening and calcification of these structures and 
were recorded in patients with varying degrees of rheumatic mitral valve involvement. 
The relatively pliable belly of the mitral valve leaflets with the disease process limited 
to the tips and chordae. Later stages results in which there is substantial fibrosis or 
calcification.  
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PLAXView(A)Diastole3,(B)Systole3 
 
Figure. 2     Figure. 3 
Transthoracic parasternal long-axis view echocardiogram recorded in a patient with 
rheumatic heart disease and mitral stenosis. In this image, recorded in early diastole,
note the doming motion of the anterior mitral valve leaflet with restriction of motion
at the tips. The belly of the leaflet (arrows) is pliable, and there is little or no fibrosis, 
calcification, or thickening of the leaflets. Also note the secondary dilation of the LA.
PSAX View 
 
Figure .4 
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Figure .5 
M-mode and 2D echo features of  Rh.MS include the  following                                                          
       1.    Thickened and calcified mitral leaflets and subvalvular apparatus 
       2.    Decreased E-F slope (M-mode) 
       3.    Hockey-stick appearance of the anterior mitral leaflet in diastole (PLAX) 
       4.    Immobility of the posterior mitral leaflet (a similar appearance can be seen 
              in Hyper eosinophilia or Ergot use) 
      5.      Fish-mouth orifice in the short-axis view  
       6.     Increased LA size, with the potential for thrombus formation 
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Planimetry from the parasternal short-axis view4,10 
 
Figure .6 
The mitral valve area can be measured with planimetry from the parasternal 
short-axis view (Figure.), which may be difficult in patients who have heavy 
calcification or who previously had commissurotomy. In patients undergoing mitral 
balloon valvuloplasty, an echo cardio graphic score26 based on valve thickness, 
calcification, mobility, and subvalvular thickening can be used to predict the outcome 
of the procedure (Table).  Patients with an echo cardio graphic score of 8 or less have 
a more favourable result from mitral balloon valvuloplasty than those with a higher 
score, but a score higher than 8 does not preclude the option of valvuloplasty 
.Commissural calcification or fusion is another important determinant of poor 
outcome after percutaneous valvuloplasty or valvotomy. Calculation of mitral valve 
area10 is the most reliable means of determining the severity of mitral stenosis, and 
several methods in addition to planimetry4 of the mitral valve are available.  
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The comprehensive echo-Doppler evaluation of mitral stenosis should include 
determination of:  
1.    Mitral valve area (MVA) by the pressure half-time (P1/2T) method: 
MVA=220/P1/2T  
2.    Peak mitral diastolic velocity by continuous wave Doppler echocardiography.  
3.     MVA by the continuity equation and by the PISA method . 
 
Mitral Valve Area by Pressure Half Time  : 
 Formula :          MVA =220/P1/2  
 
Pressure Half Time Calculation1,6 
 
 
 
 
 
 
 
 
 
Pressure Half Time Calculation of Mitral Valve : The P1/2T is the time it takes for 
the pressure gradient across the MV to decrease by half . The valve area is calculated 
using the equation, MVA -220/P1/2T where MVA -MV area and P1/2T -pressure 
half-time. This method correlates well with the invasive measurement of MVA. The 
concept behind the P1/2T method is as follows: the LV fills when blood from the LA 
crosses the MV during diastole. As the MV orifice area decreases, blood flow from 
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the LA to the LV becomes increasingly compromised, and the time required for blood 
to  flow from LA to LV becomes longer. This decreasing valve area is reflected in the 
length of time required for the pressure gradient across the MV to fall during diastole.  
The smaller the valve orifice, the longer it takes for the pressure gradient to decrease. 
In short, MV area is inversely related to the pressure half-time1 by the formula MVA -
220/P1/2T. It is important to remember that what is measured is the time it takes for 
the pressure to reach one-half of the original pressure. Pressure and velocity are 
related by the Bernoulli equation (P =4 V2). 
There are a number of important caveats to consider when assessing MV area by 
P1/2T, (as per Masuyama et al22) 
1. Atrial fibrillation. Although the P1/2T is largely independent of heart rate, if 
the heart rate for any given cycle is markedly elevated, a clear image of the 
pressure gradient fall may not be visible. Therefore, during atrial fibrillation it 
may be necessary to evaluate many beats (most labs assess at least 5 and often 
up to 10 beats). 
2. Aortic regurgitation or other conditions that increase left ventricular end-
diastolic pressure. Aortic regurgitation can shorten the time it takes for the LV 
to fill during diastole, as the LV is filled with blood from both the LA and the 
aorta. Therefore, the P1/2T6 may be “artificially” decreased leading to an 
overestimation of the MV area. This overestimation typically becomes 
clinically relevant in the setting of moderate to severe aortic regurgitation. In 
other conditions in which left ventricular end-diastolic pressure is elevated, 
such as restrictive cardio myopathy or ischemic heart disease, the rate of 
equilibration between LA and LV is increased, and the estimation of MV area 
by P1/2T can also be falsely increased. 
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3. Post PTMC- A key assumption for this equation is that the P1/2T 
measurement is largely independent of LA and left ventricular compliance. 
After PTMC, this assumption is not valid for approximately 72 hours as the 
chambers re-equilibrate. Therefore, during that time following mitral 
valvuloplasty, the P1/2T method is not considered valid.  
Estimation of the Severity of Stenosis with Doppler 21,22 
Three major technical requirements that must be satisfied if Doppler is to be used for 
this purpose :  
First, an adequate “window” into the chest for ultrasound propagation and  
reception must be found so that well formed Doppler profiles can be recorded.  
  Second, for the velocity measurement to be accurate, this window must allow 
orientation of the ultrasound beam so that it is as parallel as possible to flow through 
the valve.  
Third, the high velocities present in the disturbed jet often exceed the  Nyquist 
limit of PW Doppler, so that CW or high pulse  repetition frequency Doppler must be 
used. 
Ultrasound to estimate the severity of a valve stenosis is based principally on 
the fact that such obstructions result in an increase in the velocity of flow. In clinically 
significant mitral stenosis, the diastolic velocity of mitral flow usually exceeds 1.7 
m/s.  Thus, CW Doppler6 is required for the detection of this increased velocity and 
for recording the full spectral profile. To be noted that there is a relationship between 
the pressure increase (or gradient) across a valve and the velocity of blood flow across 
the valve. For any given pressure gradient there is a corresponding increase in 
velocity, as predicted by the 
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 Simplified Bernoulli equation:    p1-p2 = 4V2 ,  
  Where p1 = pressure distal to obstruction ; p2 = Pressure across the 
obstruction. As the stenosis becomes more severe, the valve orifice area will become 
smaller, and the velocity of flow across the orifice will increase as a function of the 
increased pressure gradient.  
Mean Gradient in Mitral Stenosis 
The best window for examination of mitral valve diastolic flow is invariably 
apical. With the transducer at the cardiac apex, the ultrasound beam should be 
directed posteriorly and slightly laterally to intercept mitral valve flow.  In normal 
individuals, PW Doppler is adequate for recording mitral valve diastolic flow. Mitral 
flow is typically laminar and biphasic, peaking in early diastole and rising again with 
atrial contraction in late diastole. The examination for mitral stenosis is usually much 
easier and more straightforward than that for aortic stenosis. The typical CW spectral 
recording of mitral stenosis demonstrates spectral broadening in diastole, with peak 
flow in early diastole and a progressive but slowed diastole descent. The secondary 
increase in diastolic velocity due to atrial contraction is absent in patients with atrial 
fibrillation. A mitral valve gradient is calculated using the modified   Bernoulli 
equation, discussed previously. As with aortic stenosis, the trans mitral pressure 
gradient may be reported in several ways. Catheterization laboratories usually report 
the mean gradient. In order to compute a comparable mean gradient for Doppler data, 
multiple instantaneous peak gradients must be measured during diastole (such as 40-
100 ms intervals) and the values averaged. At least 10 well Formed  Doppler profiles 
should be averaged in this manner if the patient is in atrial fibrillation.  
 
 
19 
 
Figure. 7 Spectral Doppler  
 
Results published to data have shown excellent agreement between CW 
Doppler estimates of the mitral valve pressure gradient, using the simplified Bernoulli 
equation, and simultaneous estimates derived from cardiac catheterization data. 
However, when the two studies are performed on separate days, the agreement 
between the two is reduced.  This apparent discrepancy derives, in part, from the 
labile nature of the mitral pressure gradient. The value of this parameter at any 
particular instant is determined not only by the extent of mitral valve obstruction 
present but also by the flow across the valve (i.e., cardiac output) and the length of the 
diastolic filling period, which in turn is determined by the heart rate. Therefore, if the 
heart rate during catheterization differs from the rate during the Doppler study, the 
pressure gradients estimated by these two techniques would be expected to differ. In 
this situation, the higher gradient would be recorded in the study performed at the 
faster heart rate. The diastolic gradient is relatively low at rest and rises significantly 
with exercise as heart rate and cardiac output rise . 
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Figure. 8 Severity of Rh.MS 
 
Continuity Equation for Mitral Valve Area Calculation 
The MV orifice area can be determined by the continuity principle. According 
to this principle, flow at any point along a tube is constant (i.e., flow                        
[Q] = VTI1 • A1 = VTI2 • A2, where VTI = velocity time integral at point x and A = 
area at point x).  Therefore, if  we know the flow at another point in the “tube” (or 
heart), e.g., the left ventricular outflow tract (LVOT), and we know the velocity time 
integral across the MV as measured by CW Doppler, we can solve for the MV area. 
Specifically, Q = VTILVOT • Area LVOT= VTIMV • Area MV. OrArea MV 
LVOT/VTIMV. This method correlates well with the invasive assessment of MVA. 
One key limitation of this method is that if there is regurgitation through The MV or 
the comparison point (e.g., aortic or pulmonic outflow tract), flow will not be the 
same at those two points .Therefore, the estimation of the MV area may not be 
accurate. 
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Figure. 9 
Figure. 10Proximal Isovelocity Surface Area7,30 
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Figure. 11 
An extension of the continuity principle is to use the proximal isovelocity 
surface area to calculate the MVA. Here, the point of “comparison” is changed from 
the aortic or pulmonic outflow tracts, for example, to the point proximal to the MV in 
the LA where Color Doppler flow aliases in the shape of a hemisphere. The area at 
that point is calculated with the equation for the area of a hemisphere, 2πr2, where r is 
the distance from the point  where the color Doppler flow aliases to the orifice of the 
MV. The velocity at the point where the color Doppler flow aliases is the nyquist limit 
on the color Doppler setting.  
Hence, we have the area and velocity at another point that we may use to solve 
for the MVA in the continuity equation. (MVA = 2πr2 • aliasing velocity/velocity 
MV). (Note: an angle correction term may need to be added to this equation in order 
to account for the influence of the two MV leaflets on the area of the sphere.  One 
benefit of this method is that, in theory, the measurement of MVA7 is not affected by 
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coexistent mitral regurgitation as flow across the MV orifice and flow across the 
aliasing point in the LA will not be significantly different in the presence of mitral 
regurgitation. However, the proximal isovelocity surface area method29 is technically 
challenging and it is not commonly used in many laboratories when evaluating mitral 
stenosis. Severe mitral stenosis by echocardiography is defined as follows:  
1. Resting mean pressure gradient is greater than or equal to 10 mmHg 
2. MVA is less than or equal to 1cm2 
3. Pressure half-time is greater than or equal to 220 ms  
              Increase in trans mitral gradient, LA pressure, and pulmonary artery pressure 
occurs with the exercise-related increase in cardiac output and heart rate. A mean 
gradient greater than 15 mmHg with exercise is considered severe mitral stenosis. A 
dobutamine induced mean mitral pressure gradient greater than or equal to 18 mmHg 
predicted clinical events with 90 percent accuracy. In patients with mitral stenosis, 
symptoms have been shown to correlate best with the degree of pulmonary 
hypertension. In this setting, patients may be treated with a beta blocker to decrease 
HR response to exercise or with mitral commissurotomy.  
 
Three-Dimensional Echocardiography 
Back ground 
 In 1960s, there were attempts to record and display ultrasound images in 3D 
format. One of the earliest studies described the acquisition of a series of parallel 
scans of a human orbit to reconstruct 3D anatomy. Despite the limited technology of 
the day, the initial studies by Mohr-Kahaly et al18 demonstrated that complex 
anatomic structures were ideally displayed using 3D techniques. Concerns about 
image quality and the computational power needed for storage and reconstruction 
greatly limited the early application of this methodology. More than a decade later, 
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investigators began to obtain 3D ultrasound images of the heart.  Through  the careful 
tracking of a transducer, a sequence of 2-dimensional (2D) echocardiograms could be 
recorded, aligned, and reconstructed into a 3D7data set. This methodology was limited 
by the need for offline data processing to create and display the 3D images. In the 
early 1990s, von Ramm and colleagues developed the first real-time 3D (RT3D) Echo 
cardio graphic scanner, capable of acquiring volumetric data at frame rates sufficient 
to depict cardiac motion. More recently, further improvements in design and 
engineering have led to the commercialization of Live3D echocardiography. This 
methodology has evolved quickly, and different versions of RT3D imaging are 
currently available on several platforms. 
 
Methodology 
1. The sagittal plane, which corresponds to a vertical, long axis view of the heart.  
2. The coronal plane, which corresponds to a 4-chamber view; and 
3. The transverse plane, which corresponds to a short-axis view. 
Each plane can be viewed from 2 sides, which represent opposite perspectives; for 
example, the transverse plane, which represents the short-axis view, can be visualized 
from the perspective of the apex or base; the coronal plane can be viewed from above 
or below; and the sagittal plane can be viewed from the left or right. The choice of 
narrow or wide-angle imaging acquisition modes depends on the cardiac structure to 
be examined. For imaging of the ventricles, it is best to use a wide-angle acquisition 
in the apical window (4- chamber) so as to include the entire ventricle. For smaller 
structures, such as the mitral valve, a narrow-angle acquisition may be adequate. The 
3D echocardiography38 technique has contributed significantly to our understanding 
A general approach is to describe cardiac structures using both the ultrasound 
plane and the viewing perspective. Three orthogonal planes are recommended:  
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of mitral valve function and anatomy. The mitral valve is particularly suited to 3D 
assessment because of the complex interrelationships among the valve, chordae, 
papillary muscles, and myocardial walls. 
Figure. 12 
Using the latest generation scanners as like Philips iE 33 system, we can use Live 
x Plane imaging to obtain truer 2D planes for analysis. We can perform a single full 
volume acquisition and crop accordinglyas per details from NC Nanda39 et al from 
Card. Clinics 2007. This would not increase significantly the scan time as it requires 
only 4 heart cycles. The resulting 3D data, set would afford the possibility to 
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retrospectively achieve any 2D view. 3D   imaging8 of the entire mitral apparatus can 
be obtained from the trans thoracic or trans esophageal approach11,40. Currently 
available scanners rely on reconstruction techniques from the trans esophageal11 
approach or real-time acquisition of a true three-dimensional data13 set from the TTE 
approach39. This technique improves the reliability for determination of involvement 
of chordal structures and further characterization of fibrosis and calcification . At this 
time, it is limited by its availability and technical complexity of offline reconstruction 
required in some systems.  
Severe Mitral stenosis in Two different Views of 3 D echo3 
 
Figure. 13      Figure. 14 
APPLICATION OF 3D ECHOCARDIOGRAPHY 
What is the additional value of 3D echocardiography for assessing mitral 
stenosis? First, the geometry of the mitral valve can be demonstrated by 3D 
echocardiography31, as seen in Figure. Second, as mentioned above, the stenotic valve 
area8 can be determined by using unique 3D views. As per Rahimtoola18 et al, 
Different 3D echo methods were used to determine the valve area in patients with 
mitral stenosis. Binder16 et al. reported real-time volumetric 3D echo9 data for the 
estimation of mitral valve area in patients with mitral valve stenosis. In 48 patients 
with mitral stenosis, MVA was determined by planimetry using volumetric real-time 
3D echo8 and compared to measurements obtained by 2D echo17 and Doppler pressure 
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half time6 (P1/2T). While 2D echo allowed planimetry of the mitral valve in 43 of 48 
patients (89%),as per Sugeng34 et al, calculation of the MVA was possible in all 
patients when 3D echo was used. Mitral valve area by 3D echo9 correlated well with 
MVA by 2D echo (r _ 0.93, mean difference, 0.09 cm2) and by P1/2T (r _ 0.87, mean 
difference, 0.16 cm2). Inter observer variability was significantly less for 3D echo18 
than for 2D echo (SD 0.08 cm2 versus SD 0.23 cm2, p _ 0.001). In this study, 3D 
echo reportedly provided accurate and highly reproducible measurements of mitral 
valve area and can easily be performed from an apical approach.  
 In another study, a more recent type of real-time 3D echo system was used for 
planimetry. This was reportedly more accurate than the Gorlin method to measure the 
valve area although the authors used three classical 2D echo methods (2D planimetry, 
pressure half time, and the PISA method) as the reference method. The authors 
concluded in this study that we should keep in mind that 3D echo planimetry may be a 
better reference method than the Gorlin method to assess the severity of rheumatic 
mitral stenosis. When 2D methods are used as reference, one may wonder whether 3D 
echocardiography9can be used independently or not in the clinical setting. They 
personally believe that the combination of conventional 2D echo especially with CW 
Doppler (for determining pressure gradients and pressure half time) and 3D echo is 
the best way to accurately assess  patho physiology37 and hemodynamics in patients 
with MS. As we all know, one should use multiple echo methods to cross-check the 
values (MVA and pressure gradients).The most striking information by 3D 
echocardiography9 is the depth and spatial relationship between two leaflets revealed 
by rotation of the mitral valve image in motion quoted in Atlas of Heart disease36.  
Not only the  severity of the stenosis but also the shape, location, and anatomic 
abnormalities of the mitral valve leaflets such as heavy calcification, as per Chu JW34 
et al  are visualized in a most intuitive way. Also, 3D PISA images give us clear 
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insight for the location and shape of PISA in MS. As stated before, the 2D PISA 
method 7,21 assumes a hemispheric shape of PISA to determine MVA, whether the 
angle is corrected or not. However, the shape of PISA showed an elongated, crescent 
shape of non-hemispheric geometry. This indicates the absolute necessity of an 
appropriate correction to use the simple PISA method for determining the MV area 
with high accuracy.    
APPLICATION OF 3D ON PERCUTANEOUS MITRAL COMMISSUROTOMY  
Application of 3D echocardiography for commissurotomy  has been reported 
many times. The 3D echocardiography technique has contributed significantly to our 
understanding of mitral valve function and anatomy. The mitral valve is particularly 
suited to 3D assessment because of the complex interrelationships among the valve, 
chordae, papillary muscles, and myocardial walls. 
 In one of these studies by Hozumi et al11, multi plane trans esophageal 
echocardiography (TEE with ECG and respiratory cycle gated image acquisition) was 
used in 19 patients undergoing balloon mitral commissurotomy . The mitral valve was 
viewed en face as if looking up from the left ventricle. The mean mitral valve area (by 
pressure half time from the Doppler of the 2D echocardiogram) increased after 
commissurotomy from 0.86 _0.06 cm2 to 2.07 _0.10 cm2, p _ 0.0001. This was 
similar to the mitral valve areas obtained by planimetry from 3D images. 3D 
reconstructions showed a complete commissural split in 10 patients and partial 
splitting in 9 patients. In 3 of the 8 patients who had an increase in the amount of 
mitral regurgitation, 3D reconstructions were able to detect tears within the valve 
leaflet. One leaflet tear actually extended up to the mitral valve annulus and was 
associated with the only 
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case of severe mitral regurgitation19.  The authors then concluded that 3D echo cardio 
graphic reconstruction enabled visualization of the mitral valve so that commissural 
splitting and leaflet tears not seen on 2D echocardiography became visible. Thanks to 
recent developments in relatively high quality trans thoracic real-time 3D 
echocardiography, as per Abascal 19& colleagues, improvement in measurement of 
valve area and changes in valve geometry after the balloon commissurotomy was 
reported. Trans thoracic real-time 3D echo, instead of multi plane TEE 3D 
reconstruction, could be employed to measure the valve area in patients with 
rheumatic mitral stenosis who underwent balloon  commissurotomy  
Invasive Evaluation of Mitral Valve Area 
The normal cardiac valve offers little resistance to blood flow. As valvular 
stenosis develops, there is progressively more resistance to flow, causing a pressure 
drop (pressure gradient) across the valve. At any stenotic orifice size, greater flow 
across the orifice yields a greater pressure gradient.  
In 1951, the Gorlins13 introduced an invasive method to calculate the effective 
orifice area of a stenotic valve using fundamental hydraulics. To calculate the stenotic 
valve area, the output in liters per minute that flows across the valve needs to be 
determined. For the mitral and tricuspid valves that means the flow in diastole only. 
For the mitral and tricuspid valves, the flow in diastole can be determined by 
multiplying the  diastolic filling period (DFP) (seconds per beat) and the heart rate 
(beats per minute) and dividing the result by the  
cardiac output (CO)(ml per minute). 
 Area =               Flow 
Constant × 44.3 ×√ Mean gradient 
                                                                                      or 
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CO/ (DFP or SEP) (HR) 
Constant × 44.3 ×√ Mean gradient 
Since the pressure drop or, gradient is a square root function, Since the 
pressure drop or doubling the cardiac output results in a quadrupling of the gradient. 
Note that at any particular cardiac output the valve gradient doubling the cardiac 
output results in a quadrupling of the gradient. Note that at any particular cardiac 
output the valve gradient increases exponentially as the valve area drops from 1.0 cm2 
to 0.8 cm2 to 0.6 cm2, etc. This latter has particular relevance when an intervention 
such as commissurotomy is performed. There is a marked difference in the valve 
gradient increasing the valve area from 0.6 to 0.8 cm2 compared to increasing the 
valve area the same 0.2 cm2 increment, from 0.8 to 1.0 cm2, for instance. The valve 
area measured by the Gorlin 13formula is subject to multiple potentials errors. 
Foremost is the difficulty in determining the cardiac output accurately. In low output 
states the effective orifice area is often calculated to be smaller than actual area..An 
alternative to the Gorlin formula is the simplified Hakki method  It is based on the 
fact that the DFP times the heart rate produced a number about the same as the 
Gorlin20 
Valve area =        Cardiac output (lit/minute) 
√Mean pressure gradient 
Decision making Regarding intervention  
Medical management plays only a minor role in alleviating symptoms in 
moderate and severe mitral stenosis. Therapy is predominantly directed at increasing 
the effective mitral orifice area, by open surgical commissurotomy, percutaneous 
balloon valvotomy, or mitral valve replacement. Once a decision has been made that 
the severity of mitral stenosis warrants intervention, two-dimensional 
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echocardiography plays a valuable role in determining the most appropriate 
interventional or surgical technique. As a general rule, valves with heavy degrees of 
calcification, chordal shortening and fibrosis, and prominent subvalvar involvement, 
are not good candidates for either surgical or interventional correction. A mitral valve 
score has been proposed to further characterize and stratify the degree to which the 
valve is anatomically compromised. The components of the score are leaflet 
thickening, leaflet mobility, calcification, and subvalvular involvement. There is a 
direct relationship between the valve score and the likelihood of successful balloon 
valvotomy, with higher scores mitigating against successful intervention. In general, 
calcification and subvalvular involvement represent a disproportionate contribution to 
the likelihood of technical failure at the time of balloon valvotomy. Individuals with a 
mitral valve score of 8 typically are excellent candidates for balloon valvotomy, and 
those with scores greater than 12 are less likely to have a satisfactory result. The issue 
of balloon valvotomy and intra procedural monitoring success of this procedure with 
trans esophageal echo is established, which deals with monitoring of operative and 
interventional procedures. Although percutaneous intervention began with coronary 
angioplasty and other interventional tools , the concept of treating diseased heart 
valves began soon thereafter. The initial thrust was to open stenotic pulmonic, mitral, 
and aortic valves via balloon valvulo plasty for which the basic techniques and 
equipment have changed little over the last two decades. More recently, there has 
been a renewed interest in this area as exciting new therapies for percutaneous 
treatment of mitral regurgitation and percutaneous replacement of pulmonic and aortic 
valves have entered clinical testing.  
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PERCUTANEOUS TRANSVENOUS MITRAL COMMISSUROTOMY 
Percutaneous mitral commissurotomy is an important therapeutic tool in 
treating rheumatic mitral stenosis. In third world or developing countries where 
rheumatic heart disease remains prevalent, percutaneous mitral valvuloplasty is the 
treatment of choice for treating patients with mitral stenosis. 
Mechanisms 
Percutaneous mitral valvuloplasty is more appropriately called percutaneous 
mitral commissurotomy because the balloon dilatation improves the valve orifice by 
separating the fused mitral commissures. As shown by echocardiographic, 
fluoroscopic, and anatomic studies, the expanding balloon splits fused commissures in 
the same manner as a surgical commissurotomy. 
Patient Selection 
Patients should be selected for percutaneous mitral commissurotmy based on 
both clinical and anatomic factors. In most cases they should be symptomatic, and 
mitral valve area as measured by echocardiography and hemodynamics should be 
<1.5 cm2. Unlike for valve surgery, the presence of pulmonary hypertension or 
abnormal left ventricular function is not a contraindication. Patients with anatomically 
suitable valves who have developed re stenosis (commissural refusion) after prior 
surgical or balloon commissurotomy can also undergo percutaneous mitral  
commissurotomy with results almost as good as previously untreated patients  
Although the procedure can be performed in patients of almost any age, the best 
clinical results are observed in younger patients, with less predictable long-term 
results occurring in patients older than 70 years, who are more likely to have 
deformed and calcified valves. Percutaneous mitral commissurotomy is a particularly 
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valuable tool in treating the symptomatic pregnant woman with critical mitral 
stenosis. It can also be a lifesaving emergency procedure in the patient with mitral 
stenosis and refractory pulmonary edema or cardiogenic shock . Asymptomatic 
patients should be considered for percutaneous mitral commissurotomy when they 
develop pulmonary hypertension or new-onset atrial fibrillation. A pulmonary artery 
peak systolic pressure >50 mm Hg at rest or 60 mm Hg with exercise in an otherwise 
asymptomatic patient represents disease severity that has reached the point where 
percutaneous commissurotomy should be considered . New atrial fibrillation is less 
clear an indication but should be considered, especially in patients with Mitral 
morphology well suited for PTMC.  
Contraindications  
Although the procedure can be performed at higher risk with thrombus 
localized to the left atrial appendage, thrombus within the left atrium itself is a 
contraindication to this procedure. Moderate or severe (2+ on a scale of 0 to 4, 
determined angiographically) Mitral regurgitation is also a contraindication to 
percutaneous mitral commissurotomy. Patients with mitral stenosis and aortic or 
tricuspid valve lesions that require cardiac surgery should be referred for surgery. 
Concomitant coronary disease can be treated with PCI in conjunction with 
commissurotomy when the coronary anatomy is suitable. This can be done in one 
session or staged, with the more clinically severe lesion treated first. Patients with 
significant valve deformity and echo cardio graphic scores >8 should not be excluded 
a priori from consideration for percutaneous mitral commissurotomy. There is no 
absolute contraindication to percutaneous mitral  commissurotomy  in patients with 
higher echo cardio graphic scores, but patients with echo cardio graphic  scores >8 
require an individualized approach. The valve into the left ventricle. The two balloons 
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are then inflated simultaneously across the mitral valve When properly performed, the 
double-balloon technique results in excellent improvement in mitral valve area . 
Multiple studies have shown no significant difference in hemodynamic results (mitral 
valve gradient or mitral valve area) post procedure between the double-balloon 
technique and the Inoue balloon system. 
An adaptation of the double-balloon technique uses a monorail approach to 
deliver two balloons across the mitral valve over a single guide wire. The first 
valvuloplasty balloon with a short monorail segment is passed over the wire across 
the mitral valve, followed by a second conventional balloon that is then passed over 
the wire until it is parallel with the first balloon. There are no substantial differences 
in the mechanism of delivery of force by two balloons using this approach compared 
with conventional double-wire, double-balloon technique. In the early surgical era of 
closed heart mitral commissurotomy, a metallic dilator, or commissurotome, was used 
via a left ventricular apical incision. However, the Inoue balloon technique is faster 
and less cumbersome and generally requires less fluoroscopy time than these other 
approaches .The Inoue balloon allows simple progressive upsizing of the balloon 
without withdrawing the balloon from the left atrium as an important advantage if 
larger balloon sizes are needed. The Inoue balloon system may, however, result in a 
slightly higher incidence of mitral  regurgitation. 
All ante grade approaches begin with the crucial first step of successful trans-
septal catheterization. This technique, not only requires successful access to the left 
atrium, but must also be through the proper part of the atrial septum to allow easy 
access to the mitral valve. After successful placement of a Mullins-type dilator and 
sheath into the left atrium and confirmation of its position by a hand injection of 
contrast, the patient is anti coagulated with heparin. Baseline hemodynamics are then 
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recorded, confirming the appropriate degree of mitral stenosis. Subsequently, a 
special solid-core 
 
Figure. 15 
coiled 0.025-inch guide wire is introduced into the left atrium, and the Mullins 
sheath dilator system is removed. The femoral vein and inter atrial septum are then 
dilated with a long 14F dilator over the coiled guide wire within the left atrium. The 
previously prepared, tested, and now slenderized Inoue balloon is then introduced 
over the guide wire into the left atrium. The Inoue balloon is made of nylon and 
rubber micromesh. Owing to the variable elasticity along its length, the balloon 
inflates in three distinct stages. This allows for stable positioning of the balloon 
catheter across the mitral valve, as described below. After the slenderized balloon has 
been positioned within the left atrium, the stretching tube is removed, and a pre 
shaped stylet is introduced into the Inoue balloon. The distal portion of the balloon is 
inflated slightly to aid in crossing the valve and to prevent intra chordal passage. By 
manoeuvring the balloon catheter while rotating and withdrawing the sty let, the 
balloon tip will move anteriorly and inferiorly toward the mitral orifice. After the 
balloon catheter is across the mitral orifice, the distal portion of the balloon is inflated 
36 
 
more fully and the catheter is pulled back gently to confirm that the inflated distal 
portion of the balloon is secure across the mitral valve. As further volume is added to 
the balloon, the proximal end inflates to lock the valve between the proximal and 
distal balloon. Inflation to pre calibrated volume then dilates the valve orifice to the 
corresponding preset size. The sequential filling and positioning of the Inoue balloon 
is done. It is then allowed to deflate passively before it is withdrawn into the left 
atrium. The pressure gradient across the mitral valve is measured after each balloon 
dilatation, and echocardiography may be used to assess the mitral valve area24, leaflet 
mobility, and the degree of mitral regurgitation. If the first inflation has not resulted in 
a satisfactory increase in the mitral valve area, and the degree of mitral regurgitation 
has not increased, the balloon is then readvanced across the mitral valve and inflation 
repeated with the balloon diameter increased by 1 or 2 mm by delivery of slightly 
more of the pre calibrated syringe volume in a stepwise dilatation process that is 
repeated until the desired result is achieved. 
 
 
Figure. 16 
 
 
 
 
Pre&Post PTMC  Mitral Valve area by Planimetry24 
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AIM OF THE STUDY 
 
Our aim was to assess which echo cardio graphic method has the best 
agreement with the mitral valve area (MVA) invasively evaluated by the Gorlin's 
formula. We had to evaluate the feasibility and reproducibility of Three-dimensional 
echocardiography for the estimation of MVA and the Wilkins score in patients with 
rheumatic mitral stenosis. 
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MATERIALS & METHODS 
STUDY DESIGN: 
This study is a comparative study. This study was conducted to describe the 
various methods of Mitral valve assessment in patients with Rheumatic Mitral 
Stenosis. 
Total no. of patients:   
There were totally 50 patients included in this study. 
Place of study: 
This study was conducted in Government Rajaji Hospital, Madurai. 50 
consecutive patients who were attending Cardiology out patients department fulfilling 
the inclusion criteria were included in this study. 
Inclusion Criteria: 
Patients with clinical features of Rheumatic Mitral Stenosis (as mentioned in 
Proforma). 
Exclusion Criteria: 
All patients with clinical features of Rheumatic Mitral Regurgitation Grade II 
& above (as mentioned in Proforma)  
Consent: 
We got informed consent in all our study population.  All patients were 
underwent a proper systematic clinical examination as mentioned in the Proforma  
immediately after the enrolment. ECG was taken with 12 channel ECG machine. 
Routine investigations were done. Chest X-ray PA was taken in all patients.  
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Objectives: 
 To analyze the Clinical profile of patients with Rheumatic Mitral Stenosis. 
 Mitral valve area to be determined by conventional echo –Doppler methods 
and by 3D with full volume (Philips IE 33 with matrix array transducer). 
 To compare the echo cardio graphic findings with the Invasive Mitral valve 
assessment (Gorlin ’s Formula).  
 Mitral score (Wilkin’s score) has to be measured. 
 In the last decade, multiple studies depicted discrepancies between mitral valve 
orifice area (MVA) measurements obtained with the pressure half-time (P1/2 T) 
method and invasive methods during the immediate post-percutaneous mitral 
commissurotomy (PTMC) period. Our aim was to assess the accuracy of 3D full 
volume Planimetry to measure the MVA in the pre & immediate post-PTMC period. 
The invasively determined MVA was used as the gold standard.  
We hypothesised that since three-dimensional (3D) echocardiography allows a 
different and superior evaluation of mitral valve apparatus, this technique could 
increase the ability to perform an accurate MVA planimetry immediately after a 
PTMC. The use of the new Trans thoracic 3D matrix array probe (Philips, IE 33) 
allows online 3D rendering of cardiac structures enabling a fast and accurate analysis 
of cardiac structures.  
Non-invasive Evaluation:  
      A complete echo-Doppler study was performed in all patients using a Philips IE 
33 ultrasound machine. Two-dimensional echocardiographic views of the mitral valve 
were obtained from the parasternal window, and planimetry was performed. 
Continuous-wave Doppler recordings through the mitral valve were obtained from the 
apical four-chamber window, and MVA was estimated by using the formula 
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220/P1/2T.  Data required to measure the MVA using the proximal isovelocity 
surface area (PISA) method were recorded from the apical window. Three cardiac 
cycles for patients in sinus rhythm and five for patients in atrial fibrillation were 
recorded, and their results averaged for every patient.  
We used the following methods to assess the mitral valve area by 2D 
echocardiography,  
1. Pressure Half time Method: The P1/2 T is the time it takes for the pressure 
gradient across the MV to decrease by half. The valve area is calculated using 
the equation, MVA -220/P1/2 where MVA -MV area and P1/2 -pressure half-
time. This method correlates well with the invasive measurement of MVA.  
2. 2D Planimetry: In our study mitral valve area was measured by planimetry 
from the parasternal short-axis view Drawbacks noted were as follows it was 
difficult in patients who have heavy calcification or who previously had 
commissurotomy. Advantage is that it is not affected by an acute fall in 
gradient immediately following the procedure. 
Wilkins Score Analysis:   The Wilkins score was determined using 2D and 
3D echocardiography by an experienced observer at different times. 
Flexibility, calcification, and subvalvular involvement were assessed. Valvular 
thickening was not evaluated as it is an objectively measurable parameter. 
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TABLE -- Echocardiographic Score Used to Predict Outcome of PTMC(Wilkin’s 
Score)26 
Grade Mobility 
Subvalvular 
Thickening Thickening Calcification 
1 Highly mobile valve 
with only leaflet tips 
restricted 
Minimal thickening 
just below the mitral 
leaflets 
Leaflets near normal 
in thickness  
(4-5 mm) 
A single area of 
increased echo 
brightness 
2 Leaflet mid and base 
portions have normal 
mobility 
Thickening of chordal 
structures extending 
up to one third of the 
chordal length 
Midleaflets normal, 
considerable 
thickening of margins 
(5-8 mm) 
Scattered areas of 
brightness 
confined to leaflet 
margins 
3 Valve continues to 
move forward in 
diastole, mainly from 
the base 
Thickening extending 
to the distal third of 
the chords 
Thickening extending 
through the entire 
leaflet (5-8 mm) 
Brightness 
extending into the 
midportion of the 
leaflets 
4 No or minimal 
forward movement of 
the leaflets in diastole 
Extensive thickening 
and shortening of all 
chordal structures 
extending down to the 
papillary muscles 
Considerable 
thickening of all 
leaflet tissue (>8-10 
mm) 
Extensive 
brightness 
throughout much 
of the leaflet 
tissue 
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3. PISA Method: After acquiring the image in A4C view, color flow mapping is 
applied. The image is zoomed and the baseline is shifted to the Nyquist limit. 
The time velocity integral is calculated and also the radius of color aliasing 
velocity in the LA side. Mitral valve area is calculated using the MVA = 2πr2 
• aliasing velocity/velocity MV.   
4. 3DFull Volume:46   Three-dimensional echocardiography was performed 
immediately after the 2D study. The system scans a 60° x 30° three-
dimensional pyramid of data. From different acoustic windows, multiple 
cardiac cycles of the mitral valve were recorded using the "zoom" mode. 
Cardiac cycles were also acquired using the "full-volume" mode that consists 
of the acquisition of a larger single pyramid of data (120° x 60°) recorded 
during four consecutive cardiac cycles (ECG timed). All images were stored in 
a magneto optical disk or compact disk and transferred for offline analysis.  
3D planimetry was performed "en-face" at the ideal cross-section of the mitral 
valve during its greatest diastolic opening. The ideal cross-section was defined 
as the most perpendicular view on the plane with the smallest mitral valve 
orifice. Gain, time gain control and depth settings were adjusted to provide 
optimal images of the mitral valve. The slice thickness of the SAX plane was 
reduced to the smallest possible value, which still permitted visualization of 
the entire mitral valve circumference (slice thickness 0.6 –1.2 mm). For each 
beat, MVA was obtained by averaging six measurements. Beat-to-beat 
variation was analyzed by calculating the coefficient of variation and was 
compared with the intra observer variability as calculated from six MVA 
measurements. The smallest MVA45 was identified from a set of eight parallel 
short-axis cut planes of the mitral valve between the annulus and the tips of 
leaflets   (para plane echocardiography) and measured by planimetry. 
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3D Protocol: Live 3D Zoom was done in A3C view. Optimization of image 
and reduced near field, Time gain compensation in 2D done. 
Adjustment of zoom box size and positioning to include entire annulus in the 
zoom ox was done. Checking of 2D opts and gains in 3D to find the best 3D image 
was done and the image was acquired. Next, with the A3C view optimization of 2D 
image reducing the depth and reducing the near field gain and acquiring the image 
using breath holding was done.  
End systolic frame was tagged. MPR`s were aligned. In red quad the image 
was rotated so that the aortic valve and root can be seen on the left of the image. Blue 
and red plane were adjusted in such a way that it sits just above mitral annular level. 
The green plane was aligned in red quad and red in green so that they intersect the 
mitral valve at mid point. Blue quad was checked so that the red and green planes cut 
across the short axis of the annular maximum diameter. In the bottom right quad, the 
model was rotated to match 3D volume operation. The protocol level is also checked 
to select the level we wish to perform. Number of slices will change automatically. 
This can be manually changed as well. Next step is to add reference points. Placing 
annular points at insertion of leaflets into annulus following a left to right workflow is 
the next vital step. 
Editing the nadir and Aortic point at insertion of non-coronary cusp comes 
next in the 3D protocol. To edit annulus points, the navigate tools in used to move 
between slices for standard or advanced model. Next, the commissural points are 
edited on the blue plane watching the red plane changing as a reference to identify 
and position the commissural points. The leaflets are traced. The coaption and border 
points are edited next in the blue plane. If not already visualized, the papillary tips are 
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added in the blue plane until the papillary tips can be seen and labelled antero-lateral 
and postero-medial.  
Proper acquisition of 3D image44 and application of the aforementioned 3D 
protocol is the key to the assessment of mitral valve area. 
Invasive Evaluation: Invasive hemodynamic evaluation was performed within 24 h 
of the echo cardiographic1 recordings. Using the catheter-based data and the Gorlin's 
equation, the MVA was obtained. Cardiac output was determined. Left ventricle and 
left atrium pressure tracings were recorded simultaneously by using a 6F pig-tail 
catheter and a conveniently placed percutaneous trans septal catheter. Planimetry of 
the area between left atrium and left ventricle pressure tracings was averaged for five 
beats.  
Trans-septal Puncture: 
Classically, trans-septal catheterization is performed only from the right 
femoral vein, although the technique for a trans jugular approach has also been 
described. Our study was done exclusively using the trans femoral approach.  For the 
femoral approach we used a 70-cm curved Brocken borough needle, which tapers 
from 18 gauge to 21 gauge at the tip. The needle is introduced via a matching 
Brocken borough catheter or 8F Mullins sheath and dilator combination that has been 
inserted to the superior vena cava over a flexible 0.032-inch, 145-cm J guidewire. 
Once the wire has been removed and the catheter has been flushed, the Brocken 
borough needle is advanced through the catheter, with an obturator protruding slightly 
beyond the tip of the needle to avoid abrasion or puncture of the catheter wall during 
needle advancement. During needle advancement, it is essential to allow the needle 
and its direction indicator to rotate freely so that it may follow the curves of the 
catheter and venous structures; the hub of the needle should never be grasped and 
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rotated at this point. The progress of the needle tip is monitored fluoroscopically, 
looking for any sign of perforation of the catheter by the needle. The stylet is then 
removed at the diaphragm, and the needle hub is connected to a pressure manifold, 
using a stopcock with a short length of tubing, and is carefully flushed. Under 
continuous fluoroscopic and pressure monitoring, the needle and catheter are then 
held in constant relationship as they are withdrawn slowly, using both hands. The 
direction indicator is firmly controlled with the right hand and used to rotate the 
needle clockwise during this withdrawal from the superior vena cava until the arrow 
is oriented posteromedialy (4 o'clock when looking from below). As the tip of the 
catheter enters the right atrium, it moves slightly rightward (toward the patient's left). 
The needle and catheter are maintained in their postero medial orientation, and they 
continue to be withdrawn slowly. As the catheter tip slips over the bulge of the 
ascending aorta, it again moves rightward to overlie the vertebrae in the anterior 
projection. Further slow withdrawal maintaining the 4 o'clock orientation will be 
associated with a third rightward movement as the catheter tip snaps into the fossa 
ovalis. This is confirmed by the fact that advancement will cause the catheter tip to 
flex slightly (rather than move back up the atrial septum) if its tip is lodged in the 
fossa. Clear fluoroscopic evidence of fossa engagement is thus essential to successful 
trans-septal puncture. Once we are confident that the needle tip is across the inter 
atrial septum, the needle and catheter are advanced as a unit a short distance into the 
left atrium, taking care to control their motion so that the protruding needle does not 
injure left atrial structures. When the catheter is across the atrial septum, the needle is 
withdrawn and the catheter is double-flushed vigorously and connected to a manifold 
for pressure recording. We used the formula of the Gorlins who first introduced this 
invasive method to calculate 
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the effective orifice area of a stenotic valve using fundamental hydraulics. To 
calculate the stenotic valve area, the output in liters per minute that flows across the 
valve needs to be determined. For the mitral and tricuspid valves that means the flow 
in diastole only. For the mitral and tricuspid valves, the flow in diastole can be 
determined by multiplying the  diastolic filling period (DFP) (seconds per beat) and 
the heart rate (beats per minute) and dividing the result by the cardiac output (CO)(ml 
per minute).                                                                                   
Area  =     Flow 
Constant × 44.3 ×√ Mean gradient 
                                                                                      or 
                                                                                CO/ (DFP or SEP) (HR) 
                                                                                Constant × 44.3 ×√ Mean gradient 
Since the pressure drop or, gradient is a square root function, since the 
pressure drop or doubling the cardiac output results in a quadrupling of the 
gradient. Note that at any particular cardiac output the valve gradient doubling the CO 
results in a quadrupling of the gradient.  
After Trans-septal puncture. 
 
 
Figure. 17 
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Balloon Dilatation 
After the crucial first step of successful trans-septal catheterization. This 
technique, requires successful access to the left atrium, but must also be through the 
proper part of the atrial septum to allow easy access to the mitral valve. After 
successful placement of a Mullins-type dilator and sheath into the left atrium and 
confirmation of its position by a hand injection of contrast, the patient is anti 
coagulated with heparin. Baseline hemodynamics are then recorded, confirming the 
appropriate degree of mitral stenosis. Subsequently, a special solid-core coiled 0.025-
inch guide wire(LA wire) is introduced into the left atrium, and the Mullins sheath 
dilator system is removed. The femoral vein and inter atrial septum are then dilated 
with a long 14F dilator over the coiled guide wire within the left atrium. The 
previously prepared, tested, and now slenderized Accura balloon is then introduced 
over the guide wire into the left atrium. The Accura balloon is made of nylon and 
rubber micromesh. Owing to the variable elasticity along its length, the balloon 
inflates in three distinct stages. This allows for stable positioning of the balloon 
catheter across the mitral valve. After the slenderized balloon has been positioned 
within the left atrium, the stretching tube is removed, and a pre shaped stylet is 
introduced into the Inoue balloon. The distal portion of the balloon is inflated slightly 
to aid in crossing the valve and to prevent intra chordal passage. By manoeuvring the 
balloon catheter while rotating and withdrawing the sty let, the balloon tip will move 
anteriorly and inferiorly toward the mitral orifice. After the balloon catheter is across 
the mitral orifice, the distal portion of the balloon is inflated more fully and the 
catheter is pulled back gently to confirm that the inflated distal portion of the balloon 
is secure across the mitral valve. As further volume is added to the balloon, the 
proximal end inflates to lock the valve between the proximal and distal balloon. 
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Inflation to pre calibrated volume then dilates the valve orifice to the corresponding 
preset size. The sequential filling and positioning of the Inoue balloon is done. It is 
then allowed to deflate passively before it is withdrawn into the left atrium. The 
pressure gradient across the mitral valve is measured after each balloon dilatation, and 
echocardiography may be used to assess the mitral valve area24, leaflet mobility, and 
the degree of mitral regurgitation. If the first inflation has not resulted in a satisfactory 
increase in the mitral valve area, and the degree of mitral regurgitation has not 
increased, the balloon is then re advanced across the mitral valve and inflation 
repeated with the balloon diameter increased by 1 or 2 mm by delivery of slightly 
more of the pre calibrated syringe volume in a stepwise dilatation process that is 
repeated until the desired result is achieved. 
Inflated Accura balloon in Mitral position  
 
Figure. 18 
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  LA &LV Pressure  Tracings :  
                                  Pre PTMC                                                                Post PTMC 
 
Intraobserver Variability:  All the recorded images were analyzed offline at 
different times by an experienced observer. The same images were also analyzed on a 
different day by the observer.  
Statistical Analysis:   The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2008) developed by Centre for Disease 
Control, Atlanta. Using this software range, frequencies, percentages, means, standard 
deviations, chi square,   ‘p’ values and Correlation coefficient were calculated. 
Kruskul Wallis chi-square test was used to test the significance of difference between 
quantitative variables. A 'p' value less than 0.05 is taken to denote significant 
relationship. If the correlation coefficient between two variables is more than 0.5, then 
there exists correlation between those two variables. Regression  
analysis was done using SPSS –Version 17 Software package. 
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Figure.19 2D Planimetry 
                  
 
 
 
 
 
 
 
Figure. 20 Spectral Doppler 
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Figure.21 PISA 
 
Figure.22 3D Planimetry 
 
                                         
 
52 
 
RESULTS OF THE STUDY 
Fifty consecutive patients with Rheumatic Mitral stenosis comprised our study 
group (Table.1). There were 32(64%)women (Table2), with a mean age of 32.5± 10 
years(Table 3). The Mean LA size was 4.83+0.93 cm(Table 4). Mitral Peak Gradient 
was 25.7+ 6.1mmHg&Mitral Mean Gradient was 15.5 +  4.2 mmHg (Bar chart). 
Mitral stenosis was the predominant valve lesion in all of them, but concomitant 
mitral regurgitation grade I was present in four patients and aortic regurgitation grade 
I was present in two patients. None of the patients showed aortic stenosis. Regarding 
the analysis of the tricuspid valve, one of our patient showed organic tricuspid 
stenosis, but twenty two showed tricuspid regurgitation. The mean TRPG was 41.4 ± 
12 mm Hg. Following PTMC, two additional patients were noted to have moderate 
mitral regurgitation.  Forty-two patients were in normal sinus rhythm, eight in atrial 
fibrillation.  
Comparison of non-invasive with invasive Methods MVA determined by the different 
methods in the pre-PTMC period were: Pressure half-time (P1/2T): 0.86±0.23 cm2; 
2D: 0.85 ± 0.23 cm2; PISA: 0.68 ± 0.13 cm2; 3D Full volume Planimetry: 0.63 ± 
0.21cm2; and Gorlin’s method: 0.69 ± 0.15 cm2(Table5).  
Regarding the PTMC procedure, the size of the balloon was selected 
according to the patient’s height. Accordingly, the mean size of Accura balloon used 
was 24.39 ± 1.21. No deep anaesthesia was used for the PTMC.  
MVA determined by the different methods in the post-PTMC period were: 2D 
echo: 2.1+ 0.36cm2, 3D Full volume Planimetry: 1.99 ± 0.4 cm2.(Table 7). In the pre-
PTMC evaluation, the invasively determined MVA showed a better agreement with 
3D Full volume Planimetry results than with P1/2 T or 2D echo results(Table 8). 
After the PTMC, the higher accuracy of the 3D Full volume Planimetry still 
remained. Thus, using the invasively determined MVA as the gold standard, 3D Full 
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volume Planimetry has a better agreement compared to P1/2 T and 2D echo 
planimetry in both the pre- and post-PTMC periods(Table 9).  
The time required to obtain and analyse the 3D Full volume Planimetry 
images, evaluated in 50 consecutive patients, was 27 ± 5 min. The only used view for 
3D Full volume Planimetry was the apical window. Although the presence or absence 
of atrial fibrillation did not influence the agreement between the measurements with 
invasive and non-invasive techniques, this fact only affects the time of the echo 
examination. Among those patients with atrial fibrillation the mean time for the 3D 
echo evaluation was 32 ± 7 min. 3D Full volume Planimetry is, as with other echo 
modalities, affected by the quality of the acoustic window. In our study, none of the 
patients showed bad acoustic window. In 24 patients, the quality was optimal and in 
the rest considered as excellent. 
Comparison of noninvasive with invasive methods.  
Mitral valve area determined by the different methods was: pressure half-time 
(P1/2 T): 0.86±0.23 cm2; 2D: 0.85 ± 0.23 cm2; PISA: 0.68 ± 0.13 cm2; 3D Full 
volume Planimetry: 0.63 ± 0.21cm2; and Gorlin’s method: 0.69 ± 0.15 cm2(Table 10). 
Kruskul Wallis chi-square test was used to test the significance of difference between 
quantitative variables, showed a better agreement when comparing the invasively 
determined MVA with 3D Full volume Planimetry -determined MVA than when 
comparing the former with the 2D-, P1/2 T-, and PISA-determined MVA. Agreement 
between 3D Full volume Planimetry and 2D, P1/2T, and PISA was also evaluated, 
showing acceptable results. Bar charts displaying differences against average values 
between traditional non invasive and 3D Full volume Planimetry42 determined mitral 
valve area. The best three-dimensional echocardiography43 method to obtain adequate 
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images for planimetry was the 3D Full Volume by using zoom method in all patients. 
The view for 3D planimetry was the apical 3 chamber view.  
Valve Score:   Evaluation of valve score was different for 2D compared with 3D. The 
3D assessment showed the best agreement. The best intra observer agreement when 
using 2D echo was noted in the evaluation of MV calcification and for 3D in valve 
flexibility. 
In the pre-PTMC evaluation47, the invasively determined MVA showed a 
better agreement with Live3D results than with P1/2 T or 2D echo results. After the 
PTMC, the higher accuracy of the 3D Full volume Planimetry46 still remained. Thus, 
using the invasively determined MVA as the gold standard, 3D Full volume 
Planimetry has a better agreement42 compared to PISA and 2D echo planimetry in 
both the pre- and post-PTMC periods. Although PISA also compared favourably with 
invasive data in the pre-PTMC period, this agreement is lost in the post-PTMC44 
period. The Correlation Coefficient between 3D Full volume Planimetry and Invasive 
Gorlin’s is significant i.e 0.737 which is >0.5 (statistically significant) and the “r” 
value is 0.956 which is very nearer to 1.000(statistically significant).(Table 9,10) 
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Table(1):        PROFILE OF CASES STUDY 
 
 
 
 
 
 
 
 
 
 
 
Table(2):    SEX DISTRIBUTION 
 
 
 
 
 
 
 
 
 
 
 
 
VARIABLE VALUE 
Age (yrs) 32.5 + 10 
Sex Male-18(36%) 
Female – 32 (64%) 
L.A (cms) 4.83 + 0.93 
Mitral PG 25.7+  6.1 
Mitral MG 15.5 +  4.2 
 
Sex 
Cases 
No. % 
Male 18 36 
Female 32 64 
Total 50 100 
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Table(3)  :   Age Distribution 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table (4)   :   L.A. Size (in cms) 35 
 
 
 
 
 
 
                                                      
 
 
 
Age Group 
(in years) 
Cases 
No. % 
Upto 20  10 20 
21-30  11 22 
31-40 18 36 
41-50 9 18 
Above 50 2 4 
Total 50 100 
Range 
Mean 
S.D. 
13-52 yrs 
32.5 yrs 
10 yrs 
Parameter L.A. Size (in cms) 
Range 
Mean 
S.D. 
3.1-7.9 cms 
4.83 cms 
0.93 cms 
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Table(5):    Pre – PTMC MV area as measured by various methods 
 
Method Pre – PTMC MV 
area 
Difference from Correlation with Regression coeff. with 
  3D-echo Gorlins 3D-echo Gorlins 3 D-echo Gorlins 
PISA 0.68+ 0.13 0.05 + 0.17 -0.072+0.13 0.5533 0.4481 0.864 0.676 
2D PL 0.85 + 0.23 -0.22+ 0.3 0.16+  0.21 0.1431 0.161 0.126 0.14 
PHT 0.86+  0.23 -0.23+ 0.28 0.17+  0.18 0.189 0.4092 0.172 0.338 
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Table(6):  Pre PTMC MV Area Gorlin Method 
 
 
             
 
 
 
 
 
 
Table(7) :   Post PTMC MVA and MG as per Gorlin method 
 
 
 
 
 
 
 
 
 
 
Parameter Pre PTMV MV Area by
Gorlin Method 
Range 0.5-1 
Mean 0.69 
S.D. 0.15 
Parameter Post PTMC 
MVA MG 
Range 1.4-3.19 3-13 
Mean  2 6.57 
SD 0.36 2.18 
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Table (8): Correlation coefficient between the Pre PTMC MV Area 
measurements by Gorlin Method & Other methods 
 
Table (9) :  Regression coefficient between the Pre PTMC MV Area 
  Measurements by Gorlin Method and Other methods 
 
 
 
 
Method Correlation coefficient between Pre 
PTMV MV Values measured by 
Gorlin method 3DPL 
PISA 0.4481 0.5533 
2DPL 0.161 0.1431 
PHT 0.4092 0.189 
3DPL 0.737 - 
Gorlin - 0.737 
Method Regression coefficient between Pre 
PTMV MV Values measured by 
Gorlin method 3DPL 
PISA 0.676 0.864 
2DPL 0.14 0.126 
PHT 0.338 0.172 
3DPL 0.956  
Gorlin  0.956 
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Table(10): Pre – PTMC MV area as measured by various methods 
Method Pre – PTMC MV area Difference from  Correlation with  Regression coeff. With 
  3D-echo Gorlins 3D-echo Gorlins 3 D-echo Gorlins 
PISA 0.68+ 0.13 0.05 + 0.17 -0.072+0.13 0.5533 0.4481 0.864 0.676 
2D PL 0.85 + 0.23 -0.22+ 0.3 0.16+  0.21 0.1431 0.161 0.126 0.14 
PHT 0.86+  0.23 -0.23+ 0.28 0.17+  0.18 0.189 0.4092 0.172 0.338 
3D PL 0.63+  0.21 - -0.07 + 0.13 - 0.737 - 0.956 
GORLIN 0.69+  0.15 -0.07 +0.13 - 0.737 - 0.956 - 
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DISCUSSION 
Due to rapid urbanisation and overcrowding, Rheumatic Mitral Stenosis 
remains an important public health concern in developing countries.  PTMC has 
become the procedure of choice in symptomatic patients when the stenotic mitral 
valve is not heavily calcified and mitral regurgitation is not significant because it is 
cost effective and safe. This technique may also be used in patients with less 
favourable anatomic features, particularly in patients who are considered to be at high 
surgical risk such as pregnant women, very elderly patients, patients with associated 
Severe Ischemic heart disease or associated other co morbidities i.e., severe 
pulmonary, renal, or malignant diseases. The results of PTMC are equivalent to those 
of surgical, open commissurotomy and both give better results than closed mitral 
commissurotomy.   
Although the Gorlin-derived mitral valve area (MVA) has been used before 
and after PTMC, echocardiography is of paramount importance in assessing the 
indication before this procedure, as well as the success and possible complications 
afterwards. Until recently, MVA was assessed indirectly by the pressure half-time 
method, or by direct planimetry, with 2D trans thoracic echocardiography6, by 3D 
trans thoracic echocardiography3 or by 3D trans oesophageal echocardiography 
(TEE). All these methods have their advantages and limitations. Patients with Rh.MS 
who require an intervention can be easily identified using non-invasive techniques 
and the results can be predicted by a careful pre-PTMC Doppler echo cardio graphic 
evaluation. Before the PTMC, the pressure gradient, the mitral valve area, and the 
severity of valve regurgitation, can be used to evaluate patients reliably. Prior to 
PTMC, Doppler echo cardio graphic estimation of MVA 6correlates well with 
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invasive estimation. Immediately following PTMC, the P1/2 T method has been 
shown to have a poor agreement with invasive data. 
 There are various reasons for this inaccuracy including:  
1. The development of an atrial septal defect in many patients after PTMC and  
2. The P1/2 T method assumes that the left atrial and left ventricular compliances 
remain stable; this assumption is not valid in the immediate period following 
PTMC because rapid changes in the left atrial pressure and left ventricular 
filling occur  in this setting, affecting the compliance of both the left atrium 
and ventricle.  
Compared to the P1/2 T method, planimetry (2D or 3D) is not as dependent on 
haemo dynamic variables (heart rate, cardiac index, cardiac rhythm, left ventricular 
systolic and diastolic dysfunction, left ventricular and atrial compliance, left 
ventricular hypertrophy and concomitant valvular disease). Accordingly, planimetry6 
of MVA should be more accurate in the setting of PTMC. Planimetry of mitral valve 
orifice using 2D echo6 is a valid method but has its own set of limitations, especially 
following commissurotomy when the mitral orifice becomes irregular and technically 
difficult to trace, particularly if calcium is present. Trans thoracic 3D 
echocardiography 3,15was the most accurate ultrasound technique for measuring 
MVA, with a better pre- and post-procedural agreement with the invasively16 (Gorlin) 
derived MVA, compared to 2D planimetry and pressure half-time derived MVA. The 
success rate for  3D echocardiography14in 50 consecutive mitral stenosis patients in 
this centre was 100% for all methods, making Trans thoracic 3D echocardiography a 
feasible technique, with an acceptable acquisition and analysis time of approximately 
27+5 min. Post- PTMC, the agreement of 3D full volume Planimetry with the Gorlin-
derived MVA was much better, in contrast to 2D planimetry and pressure half-time-
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derived MVA24, which may be due to the hemodynamic and compliance changes 
affecting the latter, as per our study and Chen CG23 et al , observed before. Also, 
compared to conventional 2D planimetry, 3DFull volume Planimetry14 was superior, 
especially post- PTMC. In 2D planimetry23, mal positioning errors in depth and angle 
of the ultrasound beam can easily lead to an overestimation of the MVA up to 88%, 
which is not an acceptable accuracy for patient management. 
 
Furthermore, it was easier and faster to define the image plane with the 
smallest orifice area, when 3D Full volume planimetry was used, and reproducibility 
for the Wilkins score was better than for 2D echocardiography. The most striking 
information by 3D echocardiography9 in our study is the depth and spatial relationship 
between two leaflets revealed by rotation of the mitral valve image in motion with 3D 
full volume Planimetry. 
 
Similarly with PISA, which has better correlation coefficient as comparable to 
3D echo, the methodology is cumbersome to follow especially for the beginners, who 
can do easily the 3D full volume Planimetry. We also inferred that three-dimensional 
image data sets, by providing the possibility of “computer slicing” to generate 
equidistant parallel cross sections of the mitral valve independently from physically 
dictated ultrasonic windows, allow accurate and reproducible measurement of the 
MVA. 
 
In conclusion, Trans thoracic 3D echocardiography offered visualization of the 
entire mitral valve apparatus, and allowed en face views of the mitral funnel 
orifice,45,47 from which accurate measurements of the MVA can be made pre- PTMC. 
It was also a very suitable technique for monitoring both the efficacy of the PTMC 
procedure (commissural splitting, MVA before and after), as well as its complications 
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(leaflet tearing and mitral regurgitation) with a better accuracy compared to 2D 
planimetry and pressure half-time derived-MVA 3Dfull volume Planimetry9 allowed 
a different and superior evaluation of the mitral valve apparatus, improving the ability 
to obtain an accurate measurement of the MVA. Restriction of the tips and chordae, 
during the evolution of the rheumatic mitral valve disease, effectively converts the 
mitral valve apparatus into a funnel 37with its restrictive mitral valve orifice being at 
the tips of the leaflets. Due to the variable geometry of the stenotic mitral valve 
orifice, correct plane orientation frequently becomes difficult. Minor changes in depth 
and angle of the ultrasound beam led to an overestimation of the MVA13 by anywhere 
from 63% to 88%. 3D echo had already been shown to be useful to optimise the 
results and prevent the development of significant mitral regurgitation during balloon 
mitral commissurotomy13. The use of the new trans thoracic 3D11 matrix array probe 
that allowed 3D Full Volume analysis , allowed  fast visualization of the mitral valve 
apparatus and the acquisition of en face views of the mitral valve from which the 
accurate measurements of the mitral valve area can be made. This image modality 
should be routinely used to both monitor the  PTMC and obtain accurate MVA 
measurements12. In this study, 3D full volume Planimetry is the most accurate echo 
cardio graphic technique for measuring MVA. Compared with P1/2T, 2D echo 
planimetry and  PISA, 3D echo planimetry had the best agreement when compared to 
the invasively derived MVA. 
 
  Not only did this occur in the pre-PTMC period but also in the post- PTMC 
period.  Importantly, since manipulation of the 3D full volume Planimetry probe is 
similar to other clinically used Trans thoracic 2D probes, we do not need a long 
training period to be versatile with 3D image acquisition. We need to know, that 
although 3D echo provides a more accurate evaluation of the anatomy of the mitral 
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valve, as with 2D28 echo, it is importantly influenced by the quality of the acoustic 
window. Needless to say that although the new equipment provides better resolution 
and image quality, a bad acoustic window will lead to a poor analysis of the patient. 
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STUDY LIMITATIONS 
The principal limitation of this study was the use of Gorlin’s method as the 
Gold Standard. The Gorlin’s equation13 is a haemo dynamic method that has 
recognized limitations, especially in situations when rapid haemo dynamic changes 
occur, such as the post-PTMC period. Significant mitral regurgitation5,32 and the 
presence of an atrial septal defect as per Manga 27et al,  may confound measurements 
of trans-mitral volume5 flow; this could explain the slight loss of agreement between 
3Dfull volume planimetry and Gorlin estimation of MVA in the post-PTMC period, 
compared to the pre-PTMC period. The desired gold standard for comparison should 
be the true pathologic inspection of the valve14. True inspection and measurement 
would allow us to determine which method is the most accurate. Echo studies were 
performed 24 h before and 24 h after the PTMC; not immediately before and after the 
procedure. Therefore, exactly the same haemo dynamic situation was not present 
within the non-invasive and invasive situation. For the calculation of mitral valve 
area, we have used and compared the P1/2 T. Also, functional data as mitral valve 
resistance have not been calculated in the present study. Other limitations are the 
image quality and the echo- Doppler settings which could also influence MVA 
measurements. 
Clinical implications 
3D Full volume Planimetry improves the assessment of MVA in the clinical 
scenarios of early post-PTMC period, when other methods have been shown not to be 
useful. Thus, 3D Full volume Planimetry is able to  replace other non-invasive 
methods and make invasive evaluation unnecessary in this setting. 
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CONCLUSION 
  Trans thoracic 3D echocardiography offered visualization of the entire mitral 
valve apparatus, and allowed en face views of the mitral funnel orifice, from which 
accurate measurements of the MVA can be made pre- PTMC. It was also a very 
suitable technique for monitoring both the efficacy of the PTMC procedure 
(commissural splitting, MVA before and after), as well as its complications (leaflet 
tearing and mitral regurgitation) with a better accuracy compared to 2D planimetry 
and pressure half-time derived-MVA. 3D Full volume Planimetry9 allowed a different 
and superior evaluation of the mitral valve apparatus, improving the ability to obtain 
an accurate measurement of the MVA.       
Hence, Trans thoracic 3D Echocardiography is a feasible and accurate 
technique for measuring MVA in patients with Rheumatic Mitral Stenosis, in Pre, 
Intra and Post PTMC states compared to the Pressure half-time method, PISA and 2D 
echo  planimetry.  
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ABBREVIATIONS 
MVA   - Mitral valve area   
Live 3D  - Three-dimensional Echocardiography 
Rh.MS   - Rheumatic Mitral stenosis 
PTMC   - Percutaneous  Transvenous Mitral commissurotomy 
P1/2T   - Pressure Half Time of MV 
PISA   - Proximal IsovelocitySurface  area 
2D PL   - Two Dimensional Planimetry 
3DPL    -  Three Dimensional Planimetry 
NYHA    - New York Heart Association 
PLAX view   - Parasternal Long axis view 
PSAX view   -  Parasternal Short axis view 
LV   - Left Ventricle 
LA   - Left Atrium 
CW   - Continuous wave Doppler 
PW   - Pulse  wave Doppler 
TRPG   - Tricuspid  Regurgitation  Peak  Gradient 
PG    - Peak  Gradient 
MG   - Mean  Gradient 
VTI   - Velocity time integral 
LVOT   -  Left Ventricular Outflow Tract 
A4C   - Apical four chamber view 
A3C   - Apical three chamber view 
DFP   - Disatolic filling period 
SEP   - Systolic ejection period 
TEE   - Trans Esophageal Echocardiography 
ECG   - Electrocardiogram 
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3D Echo Mitral Valve Area Assessment
                   in Rheumatic Mitral Stenosis 
Name                                                                                                                 Age                                              Sex
Address                                                                                                            CD No                                                                    
Complaints:                                 Chest pain                                              Dyspnoea                                 Giddiness
                                                          Syncope                                                  Palpitation                               Cough
                                                          Pedal edema                                        Fatigue                  
Past History:                                Diabetes                                                 CVA                                             Penicillin Prophylaxis
                                                          Rheumatic Fever                                Infective Endocarditis         Embolic Phenomena       
                                                          Prior Heart Surgery
Personal History:                       Smoking                                                 Alcohol                                      Exposure to STD
                                                          Socioeconomic Status
                    
Family History:                           Rheumatic Heart Disease  
General Examination:            Pulse                                                        BP                                                Cyanosis                    
                                                        Clubbing                                                 Markers of Rh. Fever           Markers of IE
 Cardio Vascular System:       JVP                                                           Precordial bulge                    Parastemal Lift
                                                         Apex beat                                             S1  S2                                           Murmur                       
Other Systems:                         RS                                                             Abdomen                                   CNS
                                                        
Investigations:                          HB%                                                        Sugar                                            ESR
12 Lead  ECG:                              Rate                                                        Rhythm                                       Axis
                                                         LAE                                                          RVH                                              LVH
Xray Chest:                                  LAE                                                          RVH                                              LVH
ECHO Findings (Pre‐PTMC )
      General                                   EF                                                            LA size                                       Aorta  size
     Mitral Valve                           Annulus                                                DE Excursion                            EF slope
     Mitral Flow                             'E' grad                                                  'A' grad                 
     Mitral Gradient                     PG                                                           MG
     Scoring                                     Thickening                                          Mobility                                     Calcification                      
                                                         Subval. Fusion                                  
     Valve Area                             2D Planimetry                                    PHT                                              3D Planimetry
                                                        MR                                                           AS/AR                                         TS/TR
                                                        TRPG                                                      
     Others                                     Pericardial Effusion                         IAS                                                LA clot
     Disease Severity                 
ECHO Findings (Post‐PTMC )                      
      General                                   EF                                                            LA size                                        RV size
     Mitral Valve                           Annulus                                                DE Excursion                            EF slope
     Mitral Flow                             'E' grad                                                  'A' grad                 
     Mitral Gradient                     PG                                                           MG
     Scoring                                     Thickening                                          Mobility                                     Calcification                      
                                                         Subval. Fusion                                  
     Valve Area                             2D Planimetry                                    PHT                                              3D Planimetry
                                                        MR                                                           AS/AR                                         TS/TR
                                                        TRPG                                                      
     Others                                     Pericardial Effusion                         IAS                                                LA clot 
     Disease Severity                 
PTMC Procedure                     Date                                                       Balloon size                              
                                                       LVEDP‐LA grad (pre )                       LVEDP‐LA grad (post)
                                                       MR grad                                                
Sno Name Age  Sex CD No
Rh. 
Fever
LA Size 
(in CM)
TRPG
Valve 
Score
2DPL~
3DPL
PHT ~ 
3DPL
PISA ~ 
3DPL
MVA by 
Gorlins 
              CCL No/Date
1 Kumar 23 M 118051 + 6.69 35 22 42 0.6 1.04 0.7 0.45 7/16 0.59 0.25 0.15 0.50 1.4 8  2320/25.2.11              
2 Kiruthiga 18 F 170846 + 4.6 30 19 45 0.7 0.7 0.8 0.8 5/16 ‐0.10  0.00 ‐0.10  0.75 1.85 5 1394/5.7.10
3 Mayandi 25 M 195425 + 4.3 23 13 48 0.6 1 0.6 0.6 5/16 0.40 0.00 0.00 0.60 2.36 5 1395/5.7.10
4 Moorthy 40 M 199962 4.5 22 12 27 0.4 0.7 0.7 0.6 6/16 0.10 0.10 ‐0.20  0.65 2.71 3 1396/5.7.10
5 Jeyalakshmi 38 F 212517 + 3.8 23 11 40 0.7 0.9 0.8 0.37 6/16 0.53 0.43 0.33 0.42 1.7 6 1902/12.11.10
6 Selvakumar 31 M 213941 + 4.7 22 15 35 0.6 0.7 0.7 0.6 5/16 0.10 0.10 0.00 0.55 2 7 1423/12.7.10
7 Soma 50 F 221989 3.4 19 12 28 0.7 1.17 1.1 1 6/16 0.17 0.10 ‐0.30  1.00 3.19 5 1422/12.7.10
8 Muniyammal 20 F 221989 + 3.1 28 20 25 0.6 0.9 1.1 0.5 5/16 0.40 0.60 0.10 0.55 2 7 1421/12.7.10
9 Kuppayee 30 F 225391 + 6 38 30 55 0.7 0.9 1.2 0.35  7/16 0.55 0.85 0.35 0.40 1.8 6  2126/6.1.11
10 Chinnaponnu 36 F 230602 5.9 23 14 30 0.7 1.2 0.7 0.6  7/16 0.60 0.10 0.10 0.50 2.1 5 2344/2.3.11
11 Kothandam 55 M 233436 + 5.8 16 10 27 0.7 0.8 0.9 0.7  8/16 0.10 0.20 0.00 0.65 2.2 4 2219/31.1.11
12 Ponnuthai 30 F 293048 6.1 18 13 62 0.7 0.8 0.59 0.45  9/16 0.35 0.14 0.25 0.50 1.75 7 2371/16.3.11
13 Arammal 33 F 300389 + 5.7 30 18 32 0.8 0.7 1 0.6  7/16 0.10 0.40 0.20 0.70 1.9 8 2137/10.1.11
14 Veeramuthu 33 F 300496 + 5.2 29 18 110 0.6 0.6 0.9 0.4  8/16 0.20 0.50 0.20 0.50 1.6 7 2127/6.1.11
15 Sumathi 42 F 301056 + 5.2 21 16 62 0.8 1 0.9 1.2  8/16 ‐0.20  ‐0.30  ‐0.40  1.20 2.52 6 2418/25.3.11
16 Santhi 30 F 301543 + 5.3 38 20 50 1 0.5 0.7 1  7/16 ‐0.50  ‐0.30  0.00 0.80 2.25 8 2008/10.12.10
17 Valliappan 50 M 302832 5.9 30 16 31 0.6 0.4 0.8 0.5 8/16 ‐0.10  0.30 0.10 0.70 1.6 7 1373/25.6.10
18 Nagarajan 33 M 305515 + 5.2 16 11 39 0.8 1.1 1.4 0.4 8/16 0.70 1.00 0.40 0.50 1.7 6 1480/27.7.10
19 Alagunatchi 52 M 305642 6.1 32 18 84 0.6 0.7 1 0.36 8/16 0.34 0.64 0.24 0.51 1.7 8 2064/23.12.10
20 Ponnalagu 27 F 306634 4.31 30 18 55 0.7 0.61 0.85 0.8 7/16 ‐0.19  0.05 ‐0.10  0.70 2.3 7 1915/16.11.10
21 Nagammal 41 F 306818 5.56 12 8 26 0.5 0.31 0.47 9/16 ‐0.47  ‐0.16  0.03 0.57 1.7 6 1861/2.11.10
22 Prabavathy 33 F 306845 + 4.5 27 17 32 0.6 0.9 0.9 0.6 8/16 0.30 0.30 0.00 0.75 2.1 8 1434/15.7.10
23 Balasubraman 35 M 306980 5.2 22 15 42 0.7 1.1 1 1 7/16 0.10 0.00 ‐0.30  1.10 2.4 7 2403/22.3.11
24 Alamelu 36 F 307050 + 5.5 35 24 69 0.6 0.4 0.4 0.8 9/16 ‐0.40  ‐0.40  ‐0.20  0.75 1.8 7 2363/15.3.11
25 Mahalakshmi 37 F 307247 4.5 33 22 38 0.6 1.2 1.1 0.7 8/16 0.50 0.40 ‐0.10  1.10 1.8 8 1916/16.11.10
26 Pappa 40 F 307407 + 5.6 25 20 57 0.7 0.7 0.71 0.46 8/16 0.24 0.25 0.24 0.65 1.7 7 1761/7/10.10
27 Ramesh 52 M 319124 + 4.9 25 15 52 0.6 0.34 0.87 0.35 7/16 ‐0.01  0.52 0.25 0.55 1.7 6 2047/20.12.10
28 Rukmini 35 F 319513 4.5 13 7 48 0.6 0.51 0.8 0.5 9/16 0.01 0.30 0.10 0.75 2 6 2042/18.12.10
29 Panchavarnam 33 M 319789 + 3.74 22 15 64 0.3 0.98 0.55 0.5 7/16 0.48 0.05 ‐0.20  0.65 2 6 2124/6.1.11
Post PTMC
MVA    MG
Mitral   
 PG      MG
Pre‐PTMC MV Area
PISA  2DPL    PHT   3DPL   
30 Malleswari 27 F 320132 4.2 22 10 32 0.6 0.6 1.4 0.63 7/16 ‐0.03  0.77 ‐0.03  0.63 2.1 8 1478/26.7.10
31 Dhanamari 20 F 320412 + 4.3 26 21 46 0.7 0.8 0.75 0.7 8/16 0.10 0.05 0.00 0.72 1.95 9 1688/20.9.10
32 Kalaimani 28 M 321970 4.6 14 8 44 0.7 0.8 0.8 0.6 7/16 0.20 0.20 0.10 0.70 1.75 6 1728/29.9.10
33 Uma selvi            20 F 322144 + 4.1 22 14 28 0.9 1.1 1 0.9 7/16 0.20 0.10 0.00 0.85 1.95 6 1901/12.11.10
34 Jeyalakshmi 38 F 322323 4.2 25 15 32 0.7 0.9 1 0.6 8/16 0.30 0.40 0.10 0.70 1.9 7 1902/12.11.10
35 Natchiappan 44 M 322371 4.9 23 14 36 0.6 0.9 0.8 0.5 8/16 0.40 0.30 0.10 0.55 2.5 8 1479/26.7.10
36 Nagaraj 17 M 323944 + 3.8 26 14 26 0.8 0.7 0.9 0.8 7/16 ‐0.10  0.10 0.00 0.70 2.42 7 2022/13.12.10
37 Vanakkili 37 F 324198 5.6 23 13 28 0.8 1 0.9 0.7 7/16 0.30 0.20 0.10 0.80 2.2 6 1708/24.9.10
38 Jaffer ali 40 M 324198 + 4.9 27 16 34 0.7 0.9 0.7 0.6 8/16 0.30 0.10 0.10 0.75 1.9 7 1741/1.10.10
39 Panchavarnam 45 F 325662 + 5.1 26 14 26 0.8 0.7 0.8 0.9 7/16 ‐0.20  ‐0.10  ‐0.10  0.75 2.2 6 1778/11.10.10
40 Vanitha 27 F 325778 + 5.2 30 16 38 0.6 0.7 0.6 0.6 8/16 0.10 0.00 0.00 0.75 1.76 6 1826/25.10.10
41 Jeyabharathi 20 F 326039 + 4.7 22 14 32 0.8 1.1 1 0.6 8/16 0.50 0.40 0.20 0.55 1.95 7 1845/29.10.10
42 Seetharaman 26 M 326043 3.9 36 15 48 0.5 0.6 0.5 0.4 8/16 0.20 0.10 0.00 0.50 1.85 6 1869/3.11.10
43 Pandiammal 21 F 326263 4.7 30 15 35 0.5 0.9 0.8 0.5 8/16 0.40 0.30 0.00 0.45 2 5 1374/25.6.10
44 Vallikannu 38 F 326627 + 3.8 25 14 28 0.7 0.9 1 0.8 7/16 0.10 0.20 ‐0.10  0.70 1.9 8 2191/21.1.11
45 Muthumari 42 M 326744 + 3.9 28 15 28 0.9 1.3 1.2 1 7/16 0.30 0.20 ‐0.10  1.30 1.9 6 2041/18.12.10
46 Vijay 13 M 329277 4.1 28 18 58 0.6 0.8 0.7 0.3 8/16 0.50 0.40 0.30 0.45 1.6 7 1923/19.11.10
47 Thenmozhi 17 F 331242 + 4.2 26 14 30 0.9 1.1 1 0.9 7/16 0.20 0.10 0.00 0.80 2.2 8 2339/1.3.11
48 Alagammal 23 F 331312 3.5 28 18 28 0.9 1.1 1.2 0.8 7/16 0.30 0.40 0.10 1.00 1.8 7 1909/5.11.10
49 Saraswathy 44 F 332492 + 3.9 32 13 30 0.8 0.9 0.8 0.6 8/16 0.30 0.2 0.2 0.55 2 6 1424/13.7.10
50 Benazir 18 F 370870 7.9 28 15 30 0.8 1.3 1.1 0.6 8/16 0.70 0.50 0.20 0.55 1.9 7 2209/25.1.11
51
52
53
54
55
56
57
3D Echo Mitral Valve Area Assessment
                   in Rheumatic Mitral Stenosis 
Name                                                                                                                 Age                                              Sex
Address                                                                                                            CD No                                                                    
Complaints:                                 Chest pain                                              Dyspnoea                                 Giddiness
                                                          Syncope                                                  Palpitation                               Cough
                                                          Pedal edema                                        Fatigue                  
Past History:                                Diabetes                                                 CVA                                             Penicillin Prophylaxis
                                                          Rheumatic Fever                                Infective Endocarditis         Embolic Phenomena       
                                                          Prior Heart Surgery
Personal History:                       Smoking                                                 Alcohol                                      Exposure to STD
                                                          Socioeconomic Status
                    
Family History:                           Rheumatic Heart Disease  
General Examination:            Pulse                                                        BP                                                Cyanosis                    
                                                        Clubbing                                                 Markers of Rh. Fever           Markers of IE
 Cardio Vascular System:       JVP                                                           Precordial bulge                    Parastemal Lift
                                                         Apex beat                                             S1  S2                                           Murmur                       
Other Systems:                         RS                                                             Abdomen                                   CNS
                                                        
Investigations:                          HB%                                                        Sugar                                            ESR
12 Lead  ECG:                              Rate                                                        Rhythm                                       Axis
                                                         LAE                                                          RVH                                              LVH
Xray Chest:                                  LAE                                                          RVH                                              LVH
ECHO Findings (Pre‐PTMC )
      General                                   EF                                                            LA size                                       Aorta  size
     Mitral Valve                           Annulus                                                DE Excursion                            EF slope
     Mitral Flow                             'E' grad                                                  'A' grad                 
     Mitral Gradient                     PG                                                           MG
     Scoring                                     Thickening                                          Mobility                                     Calcification                      
                                                         Subval. Fusion                                  
     Valve Area                             2D Planimetry                                    PHT                                              3D Planimetry
                                                        MR                                                           AS/AR                                         TS/TR
                                                        TRPG                                                      
     Others                                     Pericardial Effusion                         IAS                                                LA clot
     Disease Severity                 
ECHO Findings (Post‐PTMC )                      
      General                                   EF                                                            LA size                                        RV size
     Mitral Valve                           Annulus                                                DE Excursion                            EF slope
     Mitral Flow                             'E' grad                                                  'A' grad                 
     Mitral Gradient                     PG                                                           MG
     Scoring                                     Thickening                                          Mobility                                     Calcification                      
                                                         Subval. Fusion                                  
     Valve Area                             2D Planimetry                                    PHT                                              3D Planimetry
                                                        MR                                                           AS/AR                                         TS/TR
                                                        TRPG                                                      
     Others                                     Pericardial Effusion                         IAS                                                LA clot 
     Disease Severity                 
PTMC Procedure                     Date                                                       Balloon size                              
                                                       LVEDP‐LA grad (pre )                       LVEDP‐LA grad (post)
                                                       MR grad                                                
